david_smoller_horizon

Horizon Discovery names executive director

pharmafile | November 5, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Horizon Discovery, david smoller 

Cambridge-based genetics research firm Horizon Discovery has appointed Dr David Smoller to be an executive director on its board.

Smoller recently joined Horizon as chief business officer as part of the company’s recent acquisition of Sage Labs (where he was chief executive) for $48 million (£29 million).

Prior to that role Smoller was previously chief scientific officer at Sigma-Aldrich and president of its research biotechnology business unit. Before joining Sigma-Aldrich he served as president of ProteoPlex, a seed stage spinout focussing on proteomics (acquired by Merck KGaA in 2003).

Advertisement

Dr Ian Gilham, chairman of Horizon’s board of directors, says: “I would like to welcome David to Horizon’s noard and I am confident that David’s deep experience in identifying and nurturing high value technologies and in building successful life sciences businesses will prove a tremendous asset as Horizon continues to grow.”

Smoller adds: “The integration of Sage Labs and Horizon is progressing well and I am delighted to be joining the Horizon board at this exciting time for the company.”

Related Content

shutterstock_123182704

Horizon and Fulcrum Therapeutics form CRISPR collaboration

Horizon Discovery has announced that it has entered into a partnership with Fulcrum Therapeutics to …

Horizon forms new cancer advisory board

UK biotech Horizon Discovery has formed a new Scientific Advisory Board (SAB) for its diagnostics …

The Gateway to Local Adoption Series

Latest content